Previous close | 80.16 |
Open | 0.00 |
Bid | 80.11 x 30000 |
Ask | 80.34 x 30000 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 0 |
Market cap | 179.196B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 8.30 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If approved, Fabhalta® will be the first oral monotherapy available in Europe for the treatment of PNH, a chronic and rare blood disorder, in both complement inhibitor-treated and -naive PNH patients with hemolytic anemia1Despite anti-C5 therapy, a large proportion of patients remain anemic, fatigued a
Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg Reinhardt as Chair of the Board of Directors as well as all other current members Shareholders approve all other proposals of the Board of Directors, including the reduction of share capital, the 2023 report on non-financial matters (for the first time submitted to shareholders under new Swiss law) and
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies 1-6 Nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy 1-6The SMART study is the first open-label clinical study of Zolgensma to include previously treat